Cannabis Has Not Yet Been Established as a Treatment for Alcohol Use Disorder
Alcohol use disorder (AUD) is a chronic medical condition that can affect a person’s health, relationships, work, and safety. Although cannabis and cannabinoid-based products have attracted interest as possible tools for managing drinking, current evidence does not support medical cannabis as an established treatment for AUD.
The proposed connection comes partly from the endocannabinoid system, a network involved in reward, stress, mood, sleep, and other functions that may also play a role in addiction. Cannabis contains many compounds, but research has focused mainly on tetrahydrocannabinol (THC) and cannabidiol (CBD). These substances have different effects: THC is intoxicating and can impair attention, coordination, and judgment, while CBD does not produce the same “high.” Evidence from laboratory and animal studies cannot, by itself, show that cannabis is safe or effective for treating alcohol addiction in people.
Human research remains limited and mixed. In a small 2024 randomized trial known as the ICONIC study, a single 800-milligram dose of CBD reduced alcohol craving and activity in a brain region involved in reward during laboratory cue-exposure tasks. However, the study included only 28 people and examined short-term responses rather than whether CBD helped participants reduce drinking or avoid relapse over time. The published ICONIC trial therefore provides an early signal for further research—not proof that CBD is an effective treatment for AUD.
A 2025 feasibility study of 44 adults produced similarly cautious results. Participants received a placebo, broad-spectrum CBD, or a full-spectrum product containing a small amount of THC for eight weeks. The full-spectrum group showed reductions in craving and some AUD symptoms, but not in the number of drinks consumed per drinking day. Because the sample was small and the study was designed primarily to assess feasibility and tolerability, its findings require replication in larger trials. The full study report describes the results as preliminary.
Other evidence has been less encouraging. Two small randomized proof-of-concept trials published in 2026 found that CBD was generally tolerated, but it did not outperform placebo on drinking, craving, mood, anxiety, or post-traumatic stress symptoms. Some participants experienced side effects that limited their dose. Taken together, these results suggest that CBD may influence craving or related brain processes in some settings, but they do not demonstrate a reliable benefit for sustained recovery. A 2024 review of cannabinoids and AUD likewise described the therapeutic evidence as emerging while noting potential risks from using cannabis and alcohol together.
There is an important distinction between treating craving and treating alcohol withdrawal. Someone who has been drinking heavily for a prolonged period may develop tremors, sweating, nausea, insomnia, seizures, or delirium after suddenly stopping. Alcohol withdrawal can be life-threatening and should not be managed with cannabis at home. The American Society of Addiction Medicine’s withdrawal guideline recommends medically supervised assessment and evidence-based treatment when needed; benzodiazepines remain the standard medication for clinically significant withdrawal because they help prevent seizures and delirium tremens.
Cannabis also has risks of its own. THC can impair driving and decision-making, worsen anxiety or paranoia in some people, and contribute to cannabis use disorder. Using cannabis and alcohol together may increase impairment, and cannabis use may complicate treatment for some people with AUD. CBD is not risk-free either: the U.S. Food and Drug Administration warns that CBD can interact with medications and may cause liver injury, particularly at higher doses or in combination with certain drugs.
For people seeking treatment, cannabis should not replace proven care. Depending on a person’s medical history and treatment goals, options may include counseling, mutual-support programs, and FDA-approved medications such as naltrexone, acamprosate, or disulfiram. The National Institute on Alcohol Abuse and Alcoholism outlines these evidence-based approaches.
Medical cannabis and purified cannabinoids may eventually have a role as adjuncts for selected patients, but that question remains unresolved. For now, the strongest conclusion is that cannabinoids are experimental in AUD treatment: preliminary studies suggest possible short-term effects on craving, while larger and longer trials are needed to determine whether they improve drinking outcomes, prevent relapse, or provide benefits that outweigh their risks.
